Quantum-Si Introduces World’s First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor
- None.
- None.
The agreement between Quantum-Si and TOMY Digital Biology to distribute Quantum-Si's protein sequencing instrument in Japan signifies a strategic expansion into a new geographical market. Japan is known for its robust research and development in life sciences, which makes it a high-potential market for advanced biotechnological tools like the Platinum® protein sequencer. This move may catalyze an increase in Quantum-Si's market share and revenue growth in the Asia-Pacific region.
By analyzing market trends, one can infer that the demand for protein sequencing and analysis is on the rise due to its applications in drug discovery, personalized medicine and diagnostics. Quantum-Si's entry into the Japanese market could enhance the company's competitive edge by establishing early partnerships and brand recognition within a key demographic of researchers and institutions.
This distribution agreement could potentially lead to increased sales volume for Quantum-Si, which investors will view favorably. The financial implications hinge on the adoption rate of the Platinum® protein sequencer by Japanese researchers. If adoption is swift and widespread, Quantum-Si may see a positive impact on its bottom line. It's important for investors to monitor the company's future earnings reports for sales data related to the Japanese market to gauge the success of this strategic initiative.
Furthermore, investors should consider the costs associated with market entry and distribution, as well as the possible need for additional support and service infrastructure in Japan. These factors will affect the net financial impact of the expansion.
The field of protein sequencing is critical for understanding biological processes and disease mechanisms. Quantum-Si's technology represents a significant advancement in this field, offering researchers the ability to sequence proteins at a scale and speed not previously possible. The collaboration with TOMY Digital Biology is a testament to the technological prowess of Quantum-Si's next-generation protein sequencer™.
For the scientific community in Japan, access to such technology could accelerate research in proteomics and open new avenues for biomarker discovery, therapeutic targets and understanding complex diseases. The long-term implications might include faster drug development cycles and more precise diagnostic tools, which would be beneficial for the healthcare industry and patients alike.
TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si’s next-generation protein sequencer™ and associated consumables throughout
TOMY Digital Biology’s commitment to delivering cutting-edge solutions and its alignment with Quantum-Si's vision for scientific innovation make this a significant step forward in providing researchers in
Jeff Hawkins, CEO of Quantum-Si, expressed his enthusiasm about this move, stating: "We are thrilled to work with TOMY Digital Biology to introduce Platinum, our revolutionary protein sequencing instrument, to the vibrant scientific community in
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com
About TOMY Digital Biology Co., Ltd.
TOMY Digital Biology Co., Ltd. spun off from TOMY Seiko, a manufacturer of scientific research instruments in 2001. TOMY Digital Biology has two functions, import and export. One department imports unique life science research products from other countries and distributes them to the
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; our ongoing leadership transition; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and the Company’s other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s Annual Report for the fiscal year ended December 31, 2022, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240118517534/en/
Investor Contact
Jeff Keyes, Chief Financial Officer
ir@quantum-si.com
Media Contact
Katherine Atkinson, SVP of Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What is the ticker symbol for Quantum-Si Incorporated?
What is the new distribution agreement announced by Quantum-Si?
Who is the CEO of Quantum-Si?
What is the significance of the partnership with TOMY Digital Biology Co., Ltd. for Quantum-Si?
What is the focus of TOMY Digital Biology Co., Ltd.?
What technology will be available for researchers in Japan through the partnership?
What is the history of TOMY Digital Biology Co., Ltd.?
What is the name of Quantum-Si's protein sequencing instrument?
